Keyphrases
Children with Cancer
100%
Ototoxicity
100%
Medical Intervention
100%
Hearing Loss in children
100%
Amifostine
60%
Cisplatin
50%
Adverse Effects
50%
Platinum Therapy
50%
Additional Treatment
50%
Sodium Thiosulfate
50%
Hepatoblastoma
40%
Randomized Controlled Trial
40%
Hearing Impairment
40%
Common Toxicity Criteria
40%
Osteosarcoma
40%
Number of Participants
40%
National Cancer Institute
40%
Confidence Interval
30%
Carboplatin
30%
Quality of Life
30%
Risk Ratio
30%
Malignancy
20%
Placebo
20%
Tumor Response
20%
Controlled Experiment
20%
Intra-arterial Cisplatin
20%
Pediatric Oncology
10%
Cancer Mortality
10%
Pediatric Malignancy
10%
International Society
10%
Selection Criteria
10%
Treatment Complications
10%
Event-free Survival
10%
Overall Survival
10%
PubMed
10%
Embase
10%
Antitumor Efficacy
10%
Disease Progression
10%
Cardiotoxicity
10%
MEDLINE
10%
Data Extraction
10%
Cochrane
10%
Recent Update
10%
Toxicity Grades
10%
Pediatric Hematology
10%
Oxaliplatin
10%
Vomiting
10%
Tinnitus
10%
Partial Response
10%
Complete Response
10%
Partial Remission
10%
One-child
10%
End of Treatment
10%
Risk of Bias Assessment
10%
Ongoing Trials
10%
Ovid
10%
World Health Organization
10%
International Clinical Trials Registry Platform (ICTRP)
10%
Conference Proceedings
10%
Review Authors
10%
Cochrane Central Register of Controlled Trials
10%
Disease Relapse
10%
High-quality Research
10%
International Conference
10%
Long-term Complications
10%
Platinum Analogs
10%
Search Methods
10%
Dosage Schedule
10%
Cochrane Review
10%
Second Primary Cancer
10%
Efficacy-toxicity
10%
WHO ICTRP
10%
Grade Estimation
10%
Loss of Life
10%
Certainty of Evidence
10%
Progression Disease
10%
Hearing Quality
10%
Renal Toxicity
10%
American Society
10%
Medicine and Dentistry
Malignant Neoplasm
100%
Ototoxicity
100%
Hearing Impairment
100%
Medical Intervention
100%
Cisplatin
70%
Amifostine
60%
Adverse Event
50%
Sodium Thiosulfate
50%
Randomized Controlled Trial
40%
Hepatoblastoma
40%
Osteosarcoma
40%
Carboplatin
30%
Quality of Life
30%
Neoplasm
20%
Childhood Cancer
20%
Cancer
20%
Controlled Clinical Trial
20%
Placebo
20%
Clinical Trial
10%
Disease
10%
Oncology
10%
Cancer Mortality
10%
Second Cancer
10%
Event Free Survival
10%
Complication of Treatment
10%
Overall Survival
10%
Systematic Review
10%
Platinum Derivative
10%
Disease Exacerbation
10%
Cardiotoxicity
10%
Tinnitus
10%
Pediatric Hematology
10%
Nephrotoxicity
10%
Oxaliplatin
10%
Drug Dose Regimen
10%
Adolescence
10%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Ototoxicity
100%
Hearing Impairment
100%
Cisplatin
70%
Amifostine
60%
Adverse Event
50%
Sodium Thiosulfate
50%
Hepatoblastoma
40%
Randomized Controlled Trial
40%
Osteosarcoma
40%
Carboplatin
30%
Neoplasm
20%
Childhood Cancer
20%
Placebo
20%
Controlled Clinical Trial
20%
Clinical Trial
10%
Disease
10%
Event Free Survival
10%
Overall Survival
10%
Remission
10%
Platinum Derivative
10%
Disease Exacerbation
10%
Cardiotoxicity
10%
Cancer Mortality
10%
Oxaliplatin
10%
Tinnitus
10%
Nephrotoxicity
10%
Second Cancer
10%